MedTrace Logo

Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer

NCT01477866 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2017-12-12

No results posted yet for this study

Summary

The main aim of the present study is to test the efficacy and safety of CITOGENEX administration in patients with colon-rectal cancer.

Conditions

  • Colonic Neoplasms

Interventions

DIETARY_SUPPLEMENT

citogenex

CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).

OTHER

conventional therapy

conventional therapy for colon-rectal cancer

Sponsors & Collaborators

  • University of Palermo

    lead OTHER

Principal Investigators

  • Giovanni Tomasello, MD · University of Palermo

  • Francesco Cappello, MD · University of Palermo

  • Provvidenza Damiani, MD · University of Palermo

  • Manfredi Rizzo, MD · University of Palermo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01477866 on ClinicalTrials.gov